¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"life-table method of survival estimation"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® five-year survival rate ÇÑ±Û ¿À³â»ýÁ¸À²
¼³¸í   
  1. µ¿ÀÏ Áúº´ÀÇ Áø´Ü È¤Àº Ä¡·á ÈÄ, 5³âÀÌ °æ°ú µÈ µÚÀÇ »ýÁ¸ÀÚ¼öÀǠǥÇö. 2. ¾ÏÀÇ Áø´Ü ¶Ç´Â Ä¡·á µÚ¿¡ °Ë»ç¸¦ ¹Ýº¹ÇÏ¿© 5³â µ¿¾È »ì¾Æ Àִ »ç¶÷ÀÇ ¹éºÐÀ². Ä¡·á ÈÄ 5³â µ¿¾È »ýÁ¸Çϸé ÀÏ´Ü Ä¡À¯µÈ °ÍÀ¸·Î °£ÁÖÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • estimation
    1. ÃßÁ¤ 2. ÃßÁ¤¹ý
  • crude survival rate
    º¸Åë»ýÁ¸À², Á¶»ýÁ¸À²
  • cumulative survival rate
    ´©Àû»ýÁ¸À²
  • disease free survival
    ¹«º´»ýÁ¸
  • five-year survival rate
    ¿À³â»ýÁ¸À²
  • half survival time
    ¹Ý°¨»ýÁ¸½Ã°£
  • relative survival rate
    »ó´ë»ýÁ¸À²
  • survival
    »ýÁ¸
  • survival analysis
    »ýÁ¸ºÐ¼®
  • survival curve
    »ýÁ¸°î¼±
  • survival function
    »ýÁ¸ÇÔ¼ö
  • survival rate
    »ýÁ¸À²
  • survival ratio
    »ýÁ¸ºñ
  • survival ration
    ±¸¸í½Ä·®
  • survival time
    »ýÁ¸±â°£
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • estimation
    ÃßÁ¤
  • method of experiment
    ½ÇÇè¹æ¹ý
  • method
    ¹æ¹ý, ¹ý
  • analytical method
    ºÐ¼®¹ý
  • blind method
    ´«°¡¸²¹ý
  • projective method
    Åõ»ç¹ý
  • reflection method
    ¹Ý»ç¹ý
  • survival analysis
    »ýÁ¸ºÐ¼®
  • selective survival bias
    ¼±ÅûýÁ¸Ä¡¿ìħ, ¼±ÅûýÁ¸¿ÀÂ÷
  • survival curve
    »ýÁ¸°î¼±
  • five-year survival rate
    ¿À³â»ýÁ¸·ü
  • survival rate
    »ýÁ¸·ü
  • survival
    »ýÁ¸
  • mean survival time
    Æò±Õ»ýÁ¸½Ã°£
  • survival time
    »ýÁ¸±â°£
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • estimation
    ÃßÁ¤
  • interval estimation
    ±¸°£ÃßÁ¤¹ý
  • point estimation
    Á¡ÃßÁ¤¹ý
  • relative risk estimation
    »ó´ëÀ§ÇèµµÃßÁ¤
  • margin estimation
    °æ°èÃßÁ¤
  • survival analysis
    »ýÁ¸ºÐ¼®
  • crude survival rate
    Á¶»ýÁ¸À²
  • cumulative survival rate
    ´©Àû»ýÁ¸À²
  • survival curve
    »ýÁ¸°î¼±
  • disease free survival
    ¹«º´»ýÁ¸
  • five-year survival rate
    ¿À³â»ýÁ¸À²
  • forward survival
    ÇâÈÄ»ýÁ¸
  • survival function
    »ýÁ¸ÇÔ¼ö
  • half survival time
    ¹Ý°¨»ýÁ¸½Ã°£
  • mean survival time
    Æò±Õ»ýÁ¸½Ã°£
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • point estimation
    Á¡ÃßÁ¤¹ý(ËøÌ§ËøËÑ).
  • relative risk estimation
    »ó´ë(-Àû) À§Çèµµ ÃßÁ¤(õÏïÒ)
  • arctic survival
    ±ØÇÑ»ýÁ¸(пùÎßæðí).
  • half survival time
    ¹Ý°¨ÀÜ»ý¼ö¸í(ËÑ˧ ËÛËÎ).
  • half survival time
    ¹Ý°¨ÀÜ»ý¼ö¸í(ÚâÊõíÑßæáøÙ¤).
  • platelet survival measurement
    Ç÷¼ÒÆÇ»ýÁ¸´ÉÃøÁ¤
  • probability of survival
    »ýÁ¸(È®)·ü(Ë×Ì¡ Ì·Ëô).
  • red blood cell survival test
    ÀûÇ÷±¸¼ö¸í½ÃÇè(îåúìϹáøÙ¤ãËúÐ).
  • relative survival rate
    »ó´ë»ýÁ¸À²
  • Abell-Kendal method
    ¾Æº§-ÄË´Þ(¹æ)¹ý
  • Brown method
    ºê¶ó¿î¹æ¹ý
  • Callianos method (of artificial respiration)
    Ä®¸®¾Æ³ë ÀΰøÈ£Èí¹ý.
  • Carrels method
    Ä«·¼¹ý.
  • Castaigne method
    Ä«½ºÅ¸Àιý.
  • Castanedas rat lung method
    Ä«½ºÅ¸³×´Ù ¼­Æó¹ý.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • life-table method of survival estimation
    »ý¸íÇ¥¹ý(»ýÁ¸ ÃßÁ¤ ¹æ¹ý)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • estimation
    ÃßÁ¤
  • interval estimation
    ±¸°£ÃßÁ¤¹ý(Ï¡ÊàõÏïÒÛö).
  • margin estimation
    °æ°è ÃßÁ¤
  • point estimation
    Á¡ÃßÁ¤¹ý(ËøÌ§ËøËÑ).
  • relative risk estimation
    »ó´ë(-Àû) À§Çèµµ ÃßÁ¤(õÏïÒ)
  • ventricular estimation
    ³ú½ÇÆò°¡(ÒàãøøÄʤ) ³ú½ÇõÀÚÀÇ .
  • carbol fuchsin method ; Ziehl-Neelsen method
    Ä«¸£º¼ Ç«½Å¹ý; Áú-´ÏÀϼ¾¹ý ¡ìÇ׻꼺¿°»ö¹ý¡í.
  • arctic survival
    ±ØÇÑ»ýÁ¸(пùÎßæðí).
  • cell survival curve
    ¼¼Æ÷»ýÁ¸°î¼±
  • combat survival
    ÀüÅõ»ýÁ¸(¡­ßæðí).
  • crude survival rate
    Á¶»ýÁ¸À²
  • cumulative survival rate
    ´©Àû»ýÁ¸À²
  • desert survival
    »ç¸·»ýÁ¸(Ë×ËÎË×Ì¡).
  • disease free survival
    ¹«º´»ýÁ¸
  • erythrocyte survival
    ÀûÇ÷±¸»ýÁ¸
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • brine flotation method
    ½Ä¿°¼öºÎÀ¯¹ý
  • crushing method
    ÆÄ°¢¹ý
  • dilution egg counting method
    Èñ¼®Ãæ¶õ°è»ê¹ý
  • natural emerging method
    ÀÚ¿¬À¯Ãâ¹ý
  • squash method
    ¾ÐÂø¹ý
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • exponential survival curve
    Áö¼ö »ýÁ¸ °î¼± (ò¦â¦ßæðíÍØàÊ)
  • survival curve
    »ýÁ¸°î¼± (ßæðíÍØàÊ)
  • agar diffusion method
    ÇÑõȮ»ê¹ý(ùÎô¸üªß¤Ûö)
  • amyloclastic method
    ¾Æ¹Ð·ÎºÐÇØ¹ý(ÝÂú°Ûö)
  • amylometric method
    "¾Æ¹Ð·ÎÀ̵åÃøÁ¤¹ý(ö´ïÒÛö), ¾Æ¹Ð·ÎÀ̵å¹ý(Ûö)"
  • analytical method
    ºÐ¼®¹ý(ÝÂà°Ûö)
  • antiglobulin method
    Ç×(ù÷)±Û·ÎºÒ¸° ¹æ¹ý(Û°Ûö)
  • Archibald method
    ¾ÆÄ¡¹ßµå¹ý(Ûö)
  • Astrtup method
    ¾Æ½ºÆ®·´¹ý(Ûö)
  • auxanographic method
    ¿Á»ç³ë±×·¡Çǹý (Ûö)
  • Bradford method
    ºê·¡µåÆ÷µå ¹ý(Ûö)
  • catalytic exchange method
    Ã˸ű³È¯¹ý(õºØÚÎßüµÛö)
  • catalytic reduction method
    Ã˸Åȯ¿ø¹ý(õºØÚü½êªÛö)
  • chain terminator method
    »ç½½Çü¼º(û¡à÷) Á¾·áÀÚ¹ý(ðûÖõí­Ûö)
  • channels ratio method
    ä³Î ºñÀ²¹ý(Ýï×ËÛö)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • estimation
    Æò°¡, ÃßÁ¤
  • margin estimation
    °æ°èÃßÁ¤
  • mean survival time
    Æò±Õ»ýÁ¸½Ã°£
  • survival
    »ýÁ¸
  • acquisition method
    ȹµæ¹æ¹ý
  • bolus-tracking method
    µ¢¾î¸®ÃßÀû¹æ¹ý
  • chemical saturation method
    È­ÇÐÆ÷È­±â¹ý
  • Chopper method
    Chopper ¹ý
  • column diffusion method
    ±âµÕÈ®»ê¹æ¹ý
  • constant field gradient spin echo method
    °íÁ¤°æ»çÀ彺ÇÉ¿¡ÄÚ¹ý
  • fast gradient recalled echo method
    °í¼Ó°æ»çȸº¹¿¡ÄÚ±â¹ý
  • liquid filled stomach method
    ¾×Ã¼Ãæ¸¸À§°Ë»ç¹ý
  • method
    ¹æ¹ý, ¹ý, (¹æ)½Ä
  • octoson scanning method
    ¿ÁÅä¼Õ½ºÄµ¹ý
  • one probe method
    ´ÜÀÏŽÃËÀÚ¹æ½Ä
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CSR central supply room; chart-stimulated recall [test]; Cheyne-Stokes respiration; continued stay revie...
HI Method Hemagglutination Inhibiting Method; Ç÷±¸ ÀÀÁý ¾ïÁ¦¹ý
ABC absolute basophil count; absolute bone conduction; acalculous biliary colic; acid balance control; a...
est ester; estimation, estimated
HOPE Healthcare Options Plan Entitlement; health-oriented physical education; holistic orthogonal paramet...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ME Magnitude Estimation
MLE Maximum Likelihood Estimation
MUNE Motor unit number estimation
BEM Boundary Elements Method
CAM Confusion Assessment Method
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • age estimation
    ¿¬·É ÃßÁ¤
  • cell survival curve
    ¼¼Æ÷ »ýÁ¸ °î¼±
  • jungle survival
    Á¤±Û »ýÁ¸
  • survival
    »ýÁ¸
  • survival rate
    »ýÁ¸À²
  • activated sludge method
    Ȱ¼º ¿À´Ï¹ý
  • agar diffusion method
    ÇÑõ È®»ê¹ý, ÇÑõ³» È®»ê¹ý
    ÇÑõÀÇ °Ö ³»¿¡¼­ ħ°­¹ÝÀÀÀ» ÇàÇÏ´Â ¹æ¹ýÀ̰í 2Á¾ ÀÌ»óÀÇ Ç׿ø ¹× Ç×ü°¡ °ü¿©ÇÏ´Â ¹ÝÀÀÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ´Â °ÍÀÌ °¡´ÉÇÏ´Ù. ¹ÝÀÀ ÀÎÀÚÀÇ ¾î´À ÇÑÂÊÀ» ÇÑõ ³»¿¡ ³ì¿©µÎ°í ´Ù¸¥ ÀÎÀÚ¸¦ È®»ê½ÃŰ´Â ´Ü¼ø È®»ê¹ý°ú ÇÑõÀÇ Áß°£Ãþ°ú ¶³¾îÁ®¼­ Ç׿ø°ú Ç×ü¸¦ È®»ê½ÃŰ´Â 2Áß È®»ê¹ý, ±×¸®°í ¸é¿ª Àü±â ¿µµ¿ÀÌ ÀÖ´Ù.
  • alkaline phosphatase antialkaline phophatase method
    ¾ËÄ®¸®¼º Æ÷½ºÆÄŸÁ¦ Ç×¾ËÄ®¸®¼º Æ÷½ºÆÄŸÁ¦¹ý
  • aspirative-irrigation method
    È©ÀÎ ¼¼Ã´¹ý
  • Barber's method
    ¹Ù¾Æ¹ö ¹ý
    ¹Ì»ý¹°À» Çö¹Ì°æ¿¡¼­ ´Ü¸®ÇÏ´Â Á¶ÀÛ¹ý.
  • Barker's method
    ¹Ù¾ÆÄ¿¹ý
    Ƽ¿À½Ã¾È¿°°ú Á¦ 2Áú»ê öÀÇ È­ÇÕ¿¡ ÀÇÇÑ ºñ»ö¹ý.
  • bioassay method
    »ý¹°ÇÐÀû °ËÁ¤¹ý
  • candle jar method
    Ä­µé Àھƹý, Ä­µé ÀÚ¾Æ ¹è¾ç¹ý
  • carbol fuchsin method
    Ä«¸£º¼ Ǫũ½Å ¹ý
  • Charter's method
    Â÷ÅÍ ¹ý
    Ä©¼Ö »ç¿ë¹ýÀÇ Çϳª·Î, ¼ÖÀÌ Ä¡¾Æ¿Í Ä¡Àº¿¡ ´ëÇÏ¿© 45¡Æ·Î Ä¡°ü ÂÊÀ¸·Î ±â¿ï¾îÁö°Ô Çϸ鼭 ¼öÆòÀ» À¯Áö½ÃŰ°í ¼ÖÀÇ ¹ÝÀº Ä¡¾Æ¿¡ ±×¸®°í ¹ÝÀº Ä¡Àº¿¡ ÀÖµµ·Ï ÇÑ ´ÙÀ½, ¾ÆÁÖ ÀÛÀº ¿øÀ» ±×¸®´Â µíÇÑ Áøµ¿ ¿îµ¿À» Áָ鼭 ÇÏ´Â ¹æ¹ý. À½½Ä Â±â¿Í Ä¡°£¿¡ ¼ÖÀÌ µé¾î°¡°Ô µÇ¾î ¸¶»çÁö ¿ªÇÒµµ ÇÑ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
estimation Any non-trivial statistical procedure that assigns to an unknown quantity (parameter) a plausible value on the basis of appropriate and pertinent data collected in a proper random sample.
(05 Mar 2000)
median survival <statistics> Median means the middle value. An equal number of people live longer as die earlier than the median.
(16 Dec 1997)
cell survival The span of viability of a cell characterised by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
(12 Dec 1998)
graft survival <haematology> The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.
(12 Dec 1998)
survival 1. A living or continuing longer than, or beyond the existence of, another person, thing, or event; an outliving.
2. Any habit, usage, or belief, remaining from ancient times, the origin of which is often unknown, or imperfectly known. "The close bearing of the doctrine of survival on the study of manners and customs." (Tylor) Survival of the fittest.
<biology> See Natural selection, under Natural.
Origin: From Survive.
Source: Websters Dictionary
(01 Mar 1998)
survival analysis A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
(12 Dec 1998)
survival rate The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
(12 Dec 1998)
survival time The period elapsing between the completion or institution of any procedure and death, the life-span of biologically or physically marked erythrocytes or other cells.
(05 Mar 2000)
disease-free survival Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
(12 Dec 1998)
tissue survival The span of viability of a tissue or an organ.
(12 Dec 1998)
five year survival rate The proportion of patients still alive five years after a diagnosis or form of treatment is completed. Usually applied to statistics of survival of cancer patients, since after five years, recurrences are much less likely to occur.
(05 Mar 2000)
5-year relative survival rate <statistics> The likelihood that a patient will not die from causes associated with his or her cancer for at least 5 years after diagnosis. This is the standard many professionals use when determining someone a survivor of cancer.
(16 Dec 1997)
long-term survival <oncology> Term used to describe the survival of leukaemia patients who have been disease free for prolonged periods of time, usually at least five years. The chance of disease returning (relapse) decreases with time.
(13 Nov 1997)
Abbott's method A method of treatment of scoliosis by use of a series of plaster jackets applied after partial correction of the curvature by external force.
(05 Mar 2000)
Abell-Kendall method A standard method for estimation of total serum cholesterol involving saponification of cholesterol ester by hydroxide, extraction with petroleum ether, and colour development with acetic anhydride-sulfuric acid; the method avoids interference by bilirubin, protein, and haemoglobin.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • estimation
    Á¸Áß
  • survival
    »ì¾Æ ³²À½
  • estimation
    ÆÇ´Ü;Àǰß;Æò°¡;Á¸Áß;°ßÀû;°³»ê
  • survival
    ÀÜÁ¸;»ì¾Æ³²À½;»ýÁ¸ÀÚ;ÀÜÁ¸¹°;¿¹ºÎÅÍÀÇ Ç³½À(½Å¾Ó)
  • chief method
    ÁÖ¿ä ¼ö´Ü
  • method
    ¹æ¹ý,¼ø¼­,¹æ½Ä
  • Ericsson method
    ¿¡¸¯½¼ ¹ý(Àΰø ¼öÁ¤¹ýÀÇ Çϳª)
  • Grams method
    ±×·¥ ¿°»ö¹ý(¿°»öÇÏ¿© ¼¼±ÕÀ» ¾ç¼º°ú À½¼ºÀ¸·Î ºÐ·ù ½Äº°ÇÏ´Â ¹ý ç¼
  • Monte Carlo method
    ¸óÅ×Ä«¸¦·Î¹ý(º¹ÀâÇÑ ¹°¸® Çö»óÀ» ¼öÇÐÀûÀ¸·Î Ç®±â À§ÇÏ¿© ³­ ¼ö Ç¥·ê »ç¿ëÇÏ´Â ¹æ¹ý)
  • Montessori method(system)
    (ÀÌÅ»¸®¾ÆÀÇ ¿©¼º ±³À°°¡ À̸§¿¡¼­) ¸óÅ×¼Ò¸®½Ä ±³À°¹ý(¾Æµ¿ÀÇ ÀÚÁÖ¼ºÀÇ ½ÅÀåÀ» Áß½ÃÇÑ ±³À°¹ý) m`
  • case method
    »ç·Ê ¿¬±¸¹ý;=CASE SYSTEM
  • critical path analysis (method)
    Å©¸®Æ¼Äà ÆÐ½º ºÐ¼®¹ý(ÇÁ·ÎÁ§Æ®ÀÇ °èȹ.°ü¸®¸¦ °úÇÐÀûÀ¸·Î ÇÏ´Â ¹æ¹ý)
  • direct method
    (¿Ü±¹¾îÀÇ)Á÷Á¢ ±³¼ö¹ý(¿Ü±¹¾î¸¸À¸·Î °¡¸£Ä¡¸ç ¹®¹ý ±³À°µµ ÇÏÁö ¾ÊÀ½)
  • discovery method
    ¹ß°ß ÇнÀ¹ý(Çлý¿¡°Ô ÀÚÁÖÀûÀÎ Áö½Ä ½Àµæ,¹®Á¦ ÇØ°áÀ» ½ÃŰ´Â ±³À°¹ý) er
  • field method
    ¾ß¿Ü ¿¬±¸¹ý !
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á